Fatty liver disease, encompassing metabolic-associated fatty liver disease (MAFLD) and alcohol-associated liver disease (ALD), is now a significant global health issue. MAFLD is closely linked to ...

In 1980, Ludwig and colleagues described the histologic features of a newly identified chronic liver condition referred to as nonalcoholic steatohepatitis (NASH) and noted that the majority of the ...

Endoplasmic reticulum (ER) stress and the unfolded protein response are often implicated in the progression of metabolic dysfunction-associated steatotic liver disease (MASLD), from simple steatosis ...

The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows improvements for patients with progressive liver disease, finds a clinical ...

Mayo Clinic researchers have identified a rare mutation in the MET gene that can directly cause metabolic dysfunction-associated steatotic liver disease. The mutation disrupts the liver’s ability to ...

Researchers at the Johns Hopkins Kimmel Cancer Center report that an artificial intelligence (AI)-based liquid biopsy test ...

Background Concomitant metabolic dysfunction-associated steatotic liver disease (MASLD) is prevalent in patients with chronic ...

Metabolic dysfunction-associated steatotic liver disease (MASLD) can cause more serious liver conditions, such as liver failure. A new study, led by Lund University in Sweden, presents new data that ...

What Is Metabolic Dysfunction-Associated Steatohepatitis? Metabolic dysfunction-associated steatohepatitis, or MASH, is a form of liver disease. MASH occurs when fat accumulates in liver cells. Plenty ...

Ipilimumab-nivolumab also linked with better survival but more toxicity in small study ...